By: P.T., STA
Drug maker Krka reported a group net profit of EUR 240.1 million for the first nine months of 2021, a year-on-year increase of 14% and the highest nine-month profit in the company’s history, on the back of revenue that increased by 1% to EUR 1.18 billion.
Chief executive Jože Colarič said the company’s priorities remained to ensure sales growth and place itself among the leading branded generic pharmaceutical companies on individual markets and in selected therapeutic classes.